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Abstract 
Inflammatory bowel disease risk factors include poor diet, and corresponding low 
intake of dietary fiber, specifically prebiotics, which is fermented by the gut micro-
biota. Dietary fibers, many of which are potential prebiotics, have hundreds to thou-
sands of unique chemical structures that may promote bacteria or bacterial groups 
to provide beneficial health effects. In vitro and in vivo animal models provide some 
support for the use of prebiotics for inflammatory bowel disease through inflam-
mation reduction. Studies using prebiotics in patients with inflammatory bowel dis-
ease are limited and focus on only a select few prebiotic substances. 
Keywords: Inflammatory bowel disease, Ulcerative colitis, Crohn disease, Prebiot-
ics, Fiber   
Introduction 
Prebiotics are fermentable carbohydrates that vary greatly in chemical struc-
ture, giving rise to digestion by specific gut microbiota and eliciting discrete 
beneficial functions. Although hundreds to thousands of fermentable dietary 
fibers, which are potential prebiotic substances, exist in nature, use of prebi-
otics in research is often limited to a few distinct structural types. Research 
centered on prebiotic interventions to beneficially modify the gut milieu is 
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increasing and includes modifying microbiota, improving intestinal barrier 
function, and producing beneficial metabolites for both local and systemic 
health benefit. Despite increasing use, limited data exist for prebiotic ben-
efit for certain conditions, including inflammatory bowel disease (IBD). This 
article reviews prebiotic types and the various ways in which they modify 
the gastrointestinal tract related to IBD. The use of select prebiotics in IBD 
is described in detail, highlighting their potential effectiveness, as well as 
the lack of evidence, for their clinical use. Recommendations for future re-
search are made. 
Prebiotics: Definition and Structure 
The term prebiotics has, over time, undergone some changes in its defini-
tion, although it still adheres to the concept of carbohydrates that make 
their way to the large intestine where they are fermented and promote ben-
eficial bacteria.1 At the time of the original definition in the 1990s, a focus 
was put on oligosaccharides, and larger soluble fibers, because it was found 
that certain of such carbohydrates promoted 2 genera of beneficial bacte-
ria, namely Bifidobacterium and Lactobacillus.2 The term prebiotics became 
synonymous with oligosaccharides, such as fructooligosaccharides (FOS) 
and galactooligosaccharides (GOS), as they were accepted in the scientific, 
although not necessarily the regulatory, community to promote a healthy 
colon through the favoring of these bacteria. It was true, too, that other di-
etary carbohydrates promote 1 or both of Bifidobacterium spp and Lacto-
bacillus spp, and in the scientific literature examples can be found that also 
are claimed as prebiotic, such as resistant starch and b-glucans. However, as 
more was learned regarding other relevant beneficial colonic bacteria and 
the importance of maintaining a favorable gut ecosystem for health, it has 
become apparent that the concept of prebiotics has a broader, and perhaps 
more complicated, role in gut health. 
Prebiotics are found within the larger class of carbohydrates known as 
dietary fiber. These carbohydrates include all plant carbohydrates taken in 
the diet, plus lignin, and although fibers can be broken down into various 
subfractions, in the current discussion fiber may best be divided into fer-
mentable and nonfermentable fibers. Because prebiotics are all ferment-
able, a case could be made for a beneficial effect of all fermentable fibers 
and that they promote beneficial bacteria. Hence, the concept of prebiotics 
could potentially take in many types of fermentable fibers comprising both 
oligosaccharides and polysaccharides. In contrast, nonfermentable fibers are 
recognized for their water-holding property and laxation capacity, although 
it is not known whether nonfermentable fibers could also induce an envi-
ronment in the colon in which beneficial bacteria might flourish. 
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Perhaps what is not well recognized by scientists and clinicians special-
izing in gastrointestinal health and the gut microbiome is the broad and 
complex range of dietary fiber chemical and physical structures that exist 
(see the review by Hamaker and Tuncil,3 2014). All dietary fibers, and there-
fore prebiotics, are composed of 1 or more sugar units (e.g., glucose, fruc-
tose, galactose, arabinose) or sugar acids (e.g., galacturonic and glucuronic 
acid) that are linked via glycosidic bonds. Although dietary fibers are chem-
ically and physically classified in various ways, for the purpose of the current 
discussion related to IBD, it is perhaps useful to think of them as (1) plant 
cell wall polysaccharides of the cereals (mostly composed of cellulose, ara-
binoxylans, b-glucans, but also small amounts of pectin and even inulin in 
wheat), legumes (cellulose, pectin, galactans), tubers (cellulose, pectin), and 
fruits and vegetables (mostly composed of cellulose, pectins, xyloglucans); 
(2) plant storage oligosaccharides and polysaccharides, such as starch (those 
entering the large intestines being resistant starch) and inulin; (3) plant ex-
udates (e.g., gum arabic); and (4) animal-based carbohydrates (e.g., galac-
tooligosaccharides, chitin/chitosan). As discussed here, most prebiotics used 
in human studies for patients with IBD are in the oligosaccharide and inulin 
classes: classes 2 and 4, respectively. Plant polysaccharides can have com-
plicated chemical structures (Fig. 1 for the example of pectin),3 which gut 
bacteria can use through specialized abilities to access and metabolize cer-
tain structural components.  
Fig. 1. Cell wall pectin chemical structure. AG, arabinogalactan; ARBN, arabinan; B, 
borate; HG, homogalacturonan; PG, pectic galactan; RG I, rhamnogalacturonan I; 
RG II, rhamnogalacturonan II. (Data from Hamaker BR, Tuncil YE. A perspective on 
the complexity of dietary fiber structures and their potential effect on the gut mi-
crobiota. J Mol Biol 2014;426(23):3842; with permission.)  
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Down to the strain level, colonic bacteria have encoded in their genomes 
the ability to degrade certain carbohydrates they encounter and to absorb 
and metabolize the simple sugars released. The authors have proposed that 
there is high specificity of bacteria for carbohydrate chemical and physical 
structures and that beneficial bacteria can potentially be favored through 
fiber selection.3 
Prebiotic Function 
Prebiotic, or fermentable dietary fiber, function in the colon depends on sev-
eral factors, including obvious ones like fiber type and structure, as well as 
an individual’s gut microbiota community members and structure. Also rele-
vant to prebiotic function are such things as cross-feeding, bacteriocins, and 
phage communities that influence how fibers are used. However, it is likely 
that prebiotic dietary fibers can shift the gut microbiome and have a ben-
eficial effect on health, because the bacteria evolved under dietary stresses 
and were selected for, in significant part, based on their ability to access 
carbohydrates and use them efficiently for their maintenance and growth. 
Fermentable dietary fibers function in the colon by providing essential 
food to the microbiota. Because individual bacteria, and groups or consor-
tia of bacteria, have different abilities to use carbohydrates and must com-
pete with other bacteria for them, there is a growing recognition that mix-
tures of fibers are more likely to promote growth of a wider range of bacteria 
than single fibers. Along with this, there is a generally accepted concept that 
more diverse bacterial communities are better for health than less diverse 
ones.4 Much still needs to be learned regarding fibers and their action in the 
colon, and what mixtures are best suited for the microbiome and health, al-
though some things are known. In addition to the function of FOS, GOS, and 
inulin in promoting Bifidobacterium and Lactobacillus, certain other bene-
ficial genera and groups of bacteria have been studied in relation to fiber 
types for their promotion. The Clostridium clusters IV and IVa bacteria have 
drawn interest because they are associated with the mucosal layer of the 
gut epithelium, and contain several of the butyrogenic bacteria in the co-
lon (i.e., Faecalibacterium prausnitzii, Eubacterium rectales, Roseburia infan-
talis); there is also some evidence that insoluble (and fermentable) fibers fa-
vor these groups.3,5,6 
Inflammatory Bowel Disease 
IBD is increasing, both in the United States and in less-developed coun-
tries.7,8 The disease is characterized by immune activation in the gastrointes-
tinal tract, causing inflammation and damage to the mucosa or submucosa. 
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Ulcerative colitis (UC) differs from Crohn disease (CD) in presentation, with 
disease activity focused on the colon and rectum in UC and intermittent dis-
ease activity throughout the gastrointestinal tract in CD. IBD is characterized 
by both activated innate and adaptive immune responses, with response 
varying by IBD type.9 Although a T-helper 1–type response is thought to be 
predominant in CD and a T-helper 2–type response in UC, the stimulation 
and deregulation of these pathways in each type of IBD is more complex 
and not so clearly delineated.10 
The cause of IBD is multifaceted, and a combination of genetic predispo-
sition and environmental stimuli promote IBD. Genetic susceptibility to IBD is 
greater in CD; genes involved in signaling between the immune system and 
microbiota have been associated with IBD susceptibility (e.g., nucleotide-
binding oligomerization domain– containing protein 2 [NOD2], interleukin 
[IL]-23R, IL-10). An immune response in genetically predisposed individu-
als can be triggered by environmental stimuli through the modern lifestyle; 
sometimes these are otherwise innocuous. For example, drugs (e.g., anti-
biotics, nonsteroidal anti-inflammatory drugs), as well as infectious agents, 
stress, and diet, may all contribute to IBD.11 Also, environmental stimuli can 
have opposing effects on IBD disease type; cigarette smoking increases CD 
risk but may be protective in UC. Some of these environmental stimuli may 
modify gut microbiota, creating an environment that is more susceptible to 
IBD development. 
What Is the Involvement of Microbiota in Inflammatory Bowel 
Disease? 
The gastrointestinal microbiota is composed of bacteria, viruses, and fungi, 
but the manipulation of just the bacterial component of the microbiota is 
the focus of the IBD literature to date. All components of the microbiota in-
timately interact with the host immune system, including communication 
between bacterial species and dendritic cells (DCs) to drive differentiation 
of T cells toward either an effector or regulatory T-cell response. In the con-
text of IBD, it is not clear whether the microbiota drive changes in the host 
immune system or the host changes the microbiota through aberrant im-
mune activation; likely it is a combination of the two interactions that con-
tributes to IBD susceptibility. 
The involvement of the gut microbiota in IBD was recently reviewed.12,13 
Evidence of the influence of the microbiota/immune system interaction on 
IBD is convincing; however, alterations in specific microbiota that increase 
IBD disease risk or disease course are not completely clear. Overall, pa-
tients with IBD have less microbial diversity and increased mucosal bacteria 
than healthy individuals.12,14 Individual bacterial species also may differ be-
tween those with IBD and healthy individuals, with more adherent-invasive 
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Escherichia coli and Enterobacteriaceae, among others,12 in those with IBD. 
In addition, several taxa may be decreased, including Bifidobacterium and 
F prausnitizii.12,15–17 CD recurrence has been associated with low levels of F 
prausnitizii.18 
Although differences in microbiota composition between healthy indi-
viduals and those with IBD provide insight into microbiota’s potential role in 
IBD, this does not indicate how, or whether, these differences contribute an 
altered intestinal milieu. Differing metabolites were found in fecal samples 
between patients with CD and healthy concordant twins.19 Compared with 
healthy subjects, fecal butyrate concentrations were lower in those with IBD 
compared with healthy controls.20 Maintenance or improvement in butyrate 
concentrations is especially important because butyrate is a primary energy 
source for the colonic mucosa, contributes to gut epithelial barrier integrity, 
and shows anti-inflammatory activity.21 More literature on the contribution 
of microbial metabolites to IBD disease course is warranted. 
Dietary Strategies to Minimize Progression and Symptoms of Inflam-
matory Bowel Disease: Is There a Niche for Prebiotics? 
Management of IBD through medication (e.g., aminosalicylates, antibiot-
ics, anti–tumor necrosis factor alpha therapy, and corticosteroids) is often 
needed to control disease activity; however, medication management is not 
always effective. This lack of efficacy may lead to uncontrolled inflammation 
and complications such as rectal bleeding, bowel obstruction, and intesti-
nal resection, the occurrence of which depends on IBD type. These com-
plications, along with intermittent diarrhea, may lead to malnutrition and 
weight loss. Whereas/although nutritional inadequacy, may be addressed 
by elemental diets or parenteral nutrition; recommendations for IBD when 
in remission or in less active disease suggest dietary fiber manipulation as 
a component of treatment. 
Low-fiber diets are recommended for acute exacerbation or strictures. 
This minimization of fiber intake may be detrimental to encouraging a ben-
eficial microbial environment. However, during remission, a high-fiber diet is 
warranted to maintain normal bowel habit, minimize gastrointestinal symp-
toms, and promote a healthy intestinal milieu. These recommendations fo-
cus largely on the inclusion of dietary fiber in the context of a diet high in 
fruits, vegetables, and whole grains. However, dietary fiber intake in the 
United States is inadequate (17 g/d),22 as it is in other countries around the 
world. Thus, supplementation with select fibers that target specific bacte-
ria and other components of gut health is warranted. As highlighted ear-
lier, a structure-function relationship exists with prebiotics, suggesting that 
a specific prebiotic could be identified to target enhancement of a desired 
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specific bacterial strain based on examining these structure-function rela-
tionships. However, on the whole, this has not been thoughtfully consid-
ered when selecting prebiotics, nor has it been fully researched. In addition, 
because uncertainty surrounds the specific bacterial taxa and metabolites 
that differ between both healthy individuals and those with IBD, as well as 
between those with UC and CD, it is currently difficult to accurately identify 
specific dietary modifiers for IBD because the targets of modification are not 
clearly known. Despite this, investigators have attempted to provide prebi-
otic interventions in both animal models and in humans. 
Use Of Prebiotics in in vitro and Animal Models as a Foundation for 
the Use in Humans with Inflammatory Bowel Disease 
A few studies have examined the effect of potential prebiotic fibers using 
in vitro fermentation of microbiota from patients with IBD. Rose and col-
leagues23 (2010) showed the effect of a fabricated butyrate-producing fiber 
on the microbiota communities of patients with IBD with inactive CD and 
active UC. The test fiber was an alginate-based starch-entrapped micro-
sphere, and application in vitro fermentation system resulted in slower fer-
mentation than FOS, but with similar butyrate levels; a maintenance of low 
pH better than FOS; and a reduction in patients with inactive CD of poten-
tially harmful gut bacteria (species of Bacteroides, Enterococcus, Fusobacte-
rium, and Veillonella) compared with FOS. 
In recent studies in our laboratory at Purdue University on in vitro fe-
cal fermentation assessment of dietary fibers on patients with CD and UC, 
many patients had microbiota with low capacity to generate short-chain 
fatty acids (SCFAs), which correlated with the loss of the Bacteroidetes phy-
lum. Patients with CD and UC microbiota had lower diversity than healthy 
controls. It seemed that the severity of dysbiosis dictates the SCFA produc-
tion with fiber supplementation. When fed in vitro a mixture of fibers con-
taining equal amounts of FOS, b-glucan, pectin, and arabinoxylan (soluble), 
there was a promotion of SCFAs and gas production in the CD group that 
was better than when any single fiber was given. In the fiber mixture group, 
the Bacteroides genus was increased, although there was no significant pat-
tern of microbiota change related to the fiber mixture among the individu-
als with CD and UC. Bacteroides was increased by all the fibers. Thus, in vi-
tro human fecal fermentation analysis seems to have potential in screening 
dietary fibers for prebiotic effect, but studies comparing in vitro with human 
intervention results must still be done. 
In animals, there are several studies using mostly the dextran sodium 
sulfate model to induce UC in mice, which show a beneficial effect of pre-
biotics on gut bacteria. For instance, prebiotic fructans increased amounts 
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of Bifidobacterium and Lactobacillus in colitis-induced mice.24,25 Larrosa and 
colleagues26 (2009) studied the potential prebiotic effect of the noncarbo-
hydrate phenolic compound, resveratrol, in rats with DSS-induced colitis 
and found increased levels of Bifidobacterium and Lactobacillus, and lower 
amounts of E coli and Enterobacteriaceae. In addition, in a mouse model of 
colitis, FOS increased luminal Bifidobacterium and reduced disease activity.27 
Overall, there is a good indication of prebiotic effect resulting in im-
provements in microbiota community structure in IBD-type conditions. A 
more systematic approach toward understanding how prebiotics could opti-
mally be used through the aforementioned, as well as additional, approaches 
is desired (e.g., with maximum effect on creating favorable microbiota shifts, 
with concomitant low levels of bloating and discomfort). 
Use of Prebiotics in Humans with Inflammatory Bowel Disease: Are 
They Effective? 
In human studies reporting treatment outcomes in patients with IBD, degree 
of disease activity is assessed through biomarkers (e.g., C-reactive protein, 
fecal calprotectin, IL-10), established indices (Crohn disease activity index 
[CDAI] or Harvey-Bradshaw index [HBI]), or self-report of specific outcomes 
such as gastrointestinal symptoms or quality-of-life improvement. In ad-
dition, and germane to this topic, microbiota composition and metabolite 
production (e.g., SCFAs) can be measured to identify the prebiotic capac-
ity of the supplement, as well as to provide a potential mechanism for dis-
ease improvement. 
As discussed here, prebiotics are often specific carbohydrate structures 
that may be categorized as a type of dietary fiber. Although several research-
ers have shown that dietary fiber from whole foods and specific high-fiber 
dietary patterns can influence IBD outcomes,28,29 no studies have been done 
that examine the impact of specific prebiotic-containing whole foods on IBD. 
Thus, evaluation of the literature to determine the impact of prebiotics on 
IBD is limited to prebiotic supplementation (Table 1). 
Mixed results exist for supplementation of fructan-based prebiotics. A 
1-group, open-label study supplemented 15 g of FOS for 3 weeks in 10 pa-
tients with CD.30 Supplementation reduced the HBI score, increased fecal Bi-
fidobacterium concentrations, and increased the percentage of IL-10–pos-
itive DCs. However, fluorescence in situ hybridization was used to assess 
changes in microbiota, a method that may not be directly comparable with 
more common sequencing methods used currently. In addition, the placebo 
response could have contributed to benefits attributed to the FOS supple-
ment.31 In a follow-up study by the same group, patients with CD were en-
rolled in a placebo-controlled randomized controlled trial (RCT) to test the 
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Table 1. Human intervention studies administering prebiotics in individuals with inflammatory bowel disease 
 Study Design/  
 Intervention    Clinical  Molecular/ 
 Duration  Sample  Prebiotic  Outcomes  Microbial Outcomes 
Fructans 
Lindsay et al,30  One group,  Moderately active CD 15 g FOS  Decrease in HBI Increase in fecal  
   2006    open label    (HBI >5)    (70% oligofructose,     (9.8 [3.1] to 6.9     Bifidobacterium, 
   3 wk     n = 10    30% inulin)       [3.4], P = .01)     P = .005; no 
    Decrease in CADI     change in mucosal  
       (250.9 [77.8] to     Bifidobacterium,  
       220.6 [127.8], P = .39)     P = .76 
    Increase in patient  Increase in mucosal  
       and physician     Bifidobacterium in 
       global assessment      those who entered 
       scores, P < .01      disease remission
    Increased borborygmi,      (n = 4), P = .03 
       P = .049, and  No change in CRP,  
       flatulence severity,       P = .12 
       P = .009 Increase in  
        IL-10–positive  
        CD11c + DC  
        (30.1% [38%] to 
        53.3% [33%],  
        P = .06) 
     Increase in DC   
        TLR4 expression 
         (36.8% [32%] to  
        75.4% [7.9%], 
         P<.001) 
Benjamin et al,32  Double-blind  Active CD   15 g FOS No difference in  No difference in  
   2011     RCT      (CDAI ≥ 220     (70% DP <10,     clinically significant     Bifidobacterium  
 4 wk    plus increased      30% DP >10)    decrease in CDAI     (P = .20) or F. prausnitzii  
     inflammation)  15 g maltodextrin      (22% FOS and     (P = .95) between groups   
  n = 103     control     39% placebo,        after treatment
       P = .067) No difference in CRP
    No difference in those     (P = .32) or  
       achieving clinical     fecal calprotectin 
       remission (11% FOS     (P = .09) between  
       and 20% placebo,      groups after  
       P = .19)     treatment 
    More flatulence  Increase in  
       (P = .004),     IL-10–positive 
       borborygmi (P = .029),     CD11c + DC 
       and abdominal pain     intensity ratio 
       (P = .048),     (1.3 [0.6] to 
       than placebo at      2.0 [1.6], P = .04) 
       treatment end  
(continued on next page) 
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Table 1 (continued). Human intervention studies administering prebiotics in individuals with inflammatory bowel disease
  Study Design/  
 Intervention    Clinical  Molecular/ 
 Duration  Sample  Prebiotic  Outcomes  Microbial Outcomes
De Preter et al,33  Double-blind  Inactive or  10 g 1:1 OF-IN  Decrease in HBI  Increase in  
   2013     RCT      moderately active  10 g maltodextrin    from 4 to 3    Bifidobacterium  
 4 wk    CD (HBI 0–12)     control     (P = .048) in     longum (P = .03) 
  n = 67        prebiotic group, no      and decrease in 
       change in placebo;     Ruminococcus  
       decrease from 7 to     gnavus (P = .03)  
       5 in moderately  Disease activity  
       active patients      correlated with  
       with CD (P = .02)     B. longum 
    32% dropout rate in     (r = 0.894, P =  .02)  
       prebiotic group     in patients with 
       vs 12% in placebo     active CD  
       because of side  Increase in relative  
       effects,     concentration of  
       P = .07    acetaldehyde  
        (P = .001) and  
        butyrate (P = .001)  
        in OF-IN group 
Casellas et al,34  Double-blind  Mild to moderate 12 g oligofructose- Decrease in clinical Decrease in fecal 
   2007     RCT    UC (index of     enriched inulin    disease activity    calprotectin with  
 2 wk    Rachmilewitz 6–19)  12 g maltodextrin    in both groups    oligofructose- 
  n = 19        (P < .05), no difference     enriched inulin  
       between groups     (P < .05)  
    Decrease in dyspepsia   No change in 
       scores with oligo-    inflammatory  
       fructose-enriched     mediator  
       inulin (P < .05)     release (P >.05) 
Germinated Barley 
Kanauchi et al,35  One group,  Mild to moderate 20–30 g germinated Reduction in total  No difference 
   2003     open label     UC     barley (48% protein,    clinical activity    in biochemical  
 24 wk   n = 21    35% fiber, 9% lipid)     index score and     parametersb 
       in 2 of the 6  Decrease in  
       components (blood     erythema, 
       in stool, nocturnal      granularity,  
       diarrhea)a    and erosiona 
Plantago ovata 
Fernandez-  Open-label RCT UC in remission 20 g P. ovata seeds Treatment effect  Increase in fecal   
   Banares et al,38  1 y   n = 105  1.5 g mesalamine    not associated with    butyrate in  
   1999       20 g P. ovata seeds     probability of     those taking  
      plus mesalamine      relapse, P = .67     P. ovata seeds,  
        P = .018c 
Fujimori et al,39  3-group,  UC in remission 2 x 109 CFU B. longum Improvement in  No change in   
   2009     randomized  n = 120 4.0 g psyllium    bowel function    C-reactive protein, 
    trial        2 x 109 CFU B. longum     subcomponent     P > .05  
 4 wk     plus 4.0 g psyllium     of IBDQ, P = .04  
Abbreviations: CRP, C-reactive protein; IBDQ, IBD quality-of-life questionnaire; OF-IN, oligofructose/inulin; RCT, randomized controlled trial; TLR, 
Toll-like receptor. 
a. P value not reported. 
b. Biochemical parameters measured were not reported. 
c. n = 7, specific treatment group not reported. 
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effectiveness of 15 g of FOS on CD disease activity.32 No differences in clini-
cal response existed between groups. In addition, no change in fecal Bifido-
bacterium or F. prausnitzii was seen with FOS intake, but the proportion of 
IL-6–positive DCs decreased and the proportion of IL-10 DCs increased with 
treatment. De Preter and colleagues33 conducted a double-blind, parallel-
group RCT using 10 g of fructan (1:1 inulin to oligofructose) versus a malto-
dextrin control. In the prebiotic group, butyrate was significantly increased 
from baseline, and HBI decreased in the entire sample as well as in patients 
with moderately active disease. In addition, Casellas and colleagues34 con-
ducted a study with a mixture of inulin and oligofructose (BENEO Synergy 
1) and reported decreases in fecal calprotectin in patients with mild to mod-
erately active UC. Importantly, side effects were common in 3 of these stud-
ies, contributing to increased dropout in 2. Although most saw a beneficial 
change in clinical disease activity indices, improvement in molecular out-
comes were not consistent between studies. 
Although fructan-containing compounds are the most well-known pre-
biotics, other fibers may have prebiotic capacity and thus may benefit pa-
tients with IBD. One such example is germinated barley. Composed of not 
only fiber (cellulose, hemicellulose, and lignin), malted barley in the form 
used in IBD studies (termed germinated barley foodstuff, GBF) contains pro-
tein and lipid as major and minor components, respectively, of the dietary 
compound. Several studies by the same researchers reported a benefit of 
this compound for patients with UC.35–37 In one study (see Table 1), these re-
searchers provided patients with UC with 20 to 30 g of GBF for 24 weeks.35 
Total clinical activity index score, as well as 2 subcomponents, were reduced 
with GBF intake; however, the magnitude of change was not clearly reported. 
Images of the colon and rectum indicated improvement in erythema, gran-
ularity, and erosion. Importantly, the study was open label with no control 
group and thus could not account for the natural change in disease activ-
ity over the study duration. In addition, this study did not assess microbiota 
or metabolites. Also, GBF was stated to be well tolerated, but no support-
ing data were presented. 
In addition, Plantago ovata (psyllium) has been used in patients with UC 
to identify the impact on remission maintenance.38,39 Supplementation of 20 
g of P. ovata seeds a day resulted in no difference in remission maintenance 
compared with mesalamine. Fecal butyrate levels increased with P. ovata in-
take; however, data were presented on only 7 subjects, and it was not stated 
from which group these subjects originated (see Table 1).38 In addition, Fu-
jimori and colleagues39 did not have a control group and thus any change 
seen with prebiotic treatment (change in bowel function–related quality of 
life) is difficult to interpret in the context of prebiotic effectiveness. 
In addition to studies providing prebiotics, several investigators have 
supplemented with synbiotics, a combination of prebiotics and probiotics, 
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with benefit for inflammation39,40 and improvement in endoscopic score.41 
These studies are not reviewed here because the probiotic component is 
likely to influence gut microbiota and other measured outcomes, thus ob-
scuring the effect of the prebiotic alone. 
Limitations of current studies specifically reporting prebiotic intake in pa-
tients with IBD include inconsistency in outcomes, methods used to assess 
these outcomes, and variations in disease activity. Thus far, identification of a 
prebiotic that consistently addresses assumedly detrimental changes in mi-
crobiota in patients with IBD (e.g., lower F. prausnitzii) has not been done in 
humans. Also, dietary intake was not assessed, thus it is not known whether 
variation in diet could have affected outcomes. In addition to the lack of 
available evidence, assumptions about prebiotic consumption to benefit pa-
tients with IBD are many. First, IBD risk likely originates early in life; supple-
menting with prebiotics may modify IBD disease activity, but it is far more 
effective to create an environment amenable to ideal microbiota develop-
ment early in life, whether through prebiotic supplementation or modifica-
tion of other environmental stimuli. Although not emphasized earlier, CD 
and UC are heterogeneous diseases; it is possible that 1 prebiotic type will 
not be effective for both CD and UC. In addition to tailoring the prebiotic 
to the disease type and stage, it is possible that a mixture of prebiotic fibers 
will be most useful to enhance the functional capacity of a variety of bacte-
ria that may have health benefits for patients with IBD. 
Summary 
Prebiotics are fermentable carbohydrates with the ability to modify gut mi-
crobiota and subsequent metabolites to improve gut health. Results from 
in vitro and animal studies provide some support for the use of prebiotics 
to modify a variety of factors, including intestinal-derived inflammation, a 
key contributor to IBD pathogenesis. Although these studies support prebi-
otic use in patients with IBD, few prospective, controlled human trials exist. 
In the studies that have been completed, the prebiotic used varies, making 
it impossible to provide consensus on its effectiveness. In addition, limited 
studies exist including functional analyses. It is important to further iden-
tify alternative prebiotics with low-bloating characteristics with minimal gas 
production to provide a tolerable fiber for beneficial modulation of the mi-
crobiota, metabolite production, and inflammation reduction. In addition, 
more needs to be known about mechanisms behind IBD and the specific 
bacteria involved before targeted prebiotics can be effective.  
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Disclosures: B.R. Hamaker is a part owner of Nutrabiotix Inc., a company that de-
velops fibers with prebiotic capacity. Dr B.R. Hamaker’s involvement in this com-
pany has no influence on his statements regarding prebiotic effectiveness for in-
flammatory bowel disease.  
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